- UnitedHealthcare coverage for Wegovy varies significantly by plan type — employer-sponsored, marketplace, Medicare Advantage, and Medicaid managed care plans each have different rules
- Prior authorization is required for nearly all UHC plans that cover Wegovy, including BMI documentation and comorbidity evidence
- The cardiovascular indication from the SELECT trial may provide an alternative coverage pathway for eligible patients
- PEAK’s insurance team handles benefits verification and prior authorization with UHC before your first visit
Note: PEAK accepts UnitedHealthcare commercial plans. We do not accept UHC Medicare Advantage or UHC Community Plan (Medicaid) products.
UHC and Wegovy overview
UnitedHealthcare is one of the largest health insurance providers in Virginia, covering millions of members across employer-sponsored, individual, Medicare, and Medicaid plans. If you carry a UHC card, the question of whether Wegovy is covered is one we hear frequently — and the answer is never simple.
Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity. It is also approved for cardiovascular risk reduction. Despite these indications, UHC does not have a single, uniform policy on Wegovy. Coverage depends entirely on your specific plan design.
UnitedHealthcare administers hundreds of different plan configurations. Each employer, government program, or marketplace product defines its own formulary, exclusions, and prior authorization criteria. Two people with UHC cards can have completely different coverage for the same medication.
Plan types and coverage
Your UHC plan type is the single biggest factor in determining whether Wegovy is covered. Here is how the major plan categories typically handle anti-obesity medications:
Employer-sponsored plans
Employer-sponsored plans are the most common source of Wegovy coverage through UHC. However, coverage is not guaranteed. The employer — not UnitedHealthcare — decides whether anti-obesity medications are included in the plan’s formulary. Large employers are more likely to include Wegovy, but many mid-size and small employers exclude weight loss medications entirely to manage costs.
If your employer uses a self-funded plan administered by UHC, the formulary decisions are made by your employer’s benefits team, not by UnitedHealthcare. This is an important distinction because it means UHC’s published formulary may not apply to your plan.
ACA marketplace plans
UHC offers marketplace plans in several states, including Virginia. Coverage for Wegovy on marketplace plans varies by plan tier and state. Anti-obesity medications are not classified as essential health benefits under the ACA, so marketplace plans are not required to cover them. Some UHC marketplace plans include Wegovy on their formulary; many do not.
Medicare Advantage
UHC is the largest Medicare Advantage carrier in the country. Historically, Medicare has not covered anti-obesity medications for weight loss. However, this is changing. Some UHC Medicare Advantage plans have begun offering limited coverage for Wegovy, particularly under the cardiovascular indication (PEAK does not accept Medicare Advantage plans). Coverage under traditional Medicare Part D remains restricted for weight management, but the cardiovascular pathway has opened new possibilities.
Medicaid managed care
UHC administers Medicaid managed care plans in several states. Medicaid coverage for Wegovy is determined at the state level and varies widely. In Virginia, Medicaid coverage for GLP-1 medications for weight management is limited. If you are on a UHC Medicaid plan, benefits verification is essential before starting treatment.
UHC individual plans, short-term plans, and plans with explicit anti-obesity medication exclusions typically do not cover Wegovy. If your plan documents include a weight loss medication exclusion, Wegovy will generally be denied regardless of medical necessity — unless the cardiovascular indication applies.
Prior authorization requirements
For UHC plans that do cover Wegovy, prior authorization is almost always required. This is a process where your prescribing clinician submits clinical documentation to UHC proving that the medication is medically necessary for you.
UHC’s typical prior authorization requirements for Wegovy include:
- BMI documentation — A documented BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea
- Comorbidity evidence — Clinical records documenting the specific comorbidities that support the medical necessity of treatment
- Supervised weight management history — Evidence of participation in a structured weight management program, which may include diet, exercise, and behavioral counseling, typically for 3 to 6 months prior to the request
- Prescriber qualifications — The prescriber must be a physician, nurse practitioner, or physician assistant with appropriate prescribing authority
Prior authorization is not a denial — it is a documentation requirement. When the clinical evidence is thorough and well-organized, approval rates improve significantly.
At PEAK, our clinical team documents everything from your first visit with UHC’s PA requirements in mind. We know what UnitedHealthcare reviewers look for because we submit these requests routinely.
Formulary placement
Where Wegovy sits on your UHC formulary directly affects what you pay out of pocket. UHC formularies organize medications into tiers, and the tier placement determines your copay or coinsurance amount.
| Formulary tier | Typical cost impact |
|---|---|
| Preferred brand (Tier 2) | Lower copay, typically $25 – $75/month |
| Non-preferred brand (Tier 3) | Higher copay, typically $150 – $300+/month |
| Specialty tier (Tier 4–5) | Coinsurance (20–33%), may require specialty pharmacy |
| Not on formulary | Not covered — full cash price ($1,300+/month) |
Wegovy is most commonly placed on the non-preferred brand or specialty tier when it is covered. This means your out-of-pocket cost may be higher than a standard copay. Your deductible status, coinsurance percentage, and out-of-pocket maximum all affect the final cost.
Novo Nordisk, the manufacturer of Wegovy, offers savings programs for eligible commercially insured patients. If your UHC plan covers Wegovy, a manufacturer savings card may reduce your copay. PEAK’s team can help you determine whether you qualify for additional savings.
The cardiovascular pathway
In March 2024, the FDA approved Wegovy for a second indication: reducing the risk of major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) in adults with established cardiovascular disease and overweight or obesity. This approval was based on the SELECT trial, which demonstrated a 20% reduction in cardiovascular events.
This is significant for UHC coverage because it creates a separate clinical pathway. If you have documented cardiovascular disease — a history of heart attack, stroke, or peripheral artery disease — your clinician may be able to submit the prior authorization under the cardiovascular indication rather than the weight management indication.
Some UHC plans that exclude weight loss medications may still cover medications prescribed for cardiovascular risk reduction. The cardiovascular indication is not a workaround — it is a legitimate FDA-approved use. Your clinician must document a genuine cardiovascular history. At PEAK, we evaluate every patient individually and use the most appropriate clinical pathway for both treatment and coverage.
If you’re denied
A denial from UnitedHealthcare is not the end of the process. UHC has a structured appeals process with specific timelines and procedures. Understanding these timelines is critical to protecting your rights.
If your prior authorization for Wegovy is denied, here are the steps available:
- Peer-to-peer review — Your prescribing clinician can request a phone call with a UHC medical director to discuss your case. This is often the fastest way to overturn a denial when the clinical documentation is strong. UHC typically schedules peer-to-peer reviews within 5 to 7 business days of the request.
- First-level appeal — You or your clinician can submit a formal appeal within 180 days of the denial. UHC is required to respond to standard appeals within 30 calendar days. For urgent situations, expedited appeals must be decided within 72 hours.
- External review — If UHC upholds the denial on appeal, you may have the right to request an independent external review. An external reviewer not affiliated with UHC evaluates your case against clinical evidence and coverage criteria.
- Alternative clinical pathway — If the weight management indication is denied, your clinician may explore the cardiovascular indication or recommend alternative FDA-approved medications that are on your UHC formulary.
Standard appeal: 30 calendar days for a decision. Expedited appeal: 72 hours. External review: varies by state, typically 45 days. Keep copies of all denial letters and appeal submissions — your clinician’s office should manage this documentation, but having your own records is important.
How PEAK helps with UHC
Working through UnitedHealthcare coverage is one of the most common challenges our patients face. At PEAK, we handle the insurance process before you walk through the door.
Here is what our process looks like:
- Benefits verification. We check your UHC plan for Wegovy coverage, formulary tier, and any exclusions — before your first appointment. We contact UHC directly and verify the specifics of your plan, not just what the published formulary says.
- Prior authorization. Our clinical team prepares and submits your PA with the documentation UHC requires. We structure the clinical narrative around UHC’s specific criteria because we work with their review process regularly.
- Denial management. If your PA is denied, we manage the appeal process, including peer-to-peer reviews with UHC medical directors and formal written appeals.
- Alternative pathways. If Wegovy is not covered under your UHC plan, we evaluate other FDA-approved options that may be on your formulary — and we assess whether the cardiovascular indication applies to your clinical profile.
We tell you what your UHC plan covers before you commit to anything. If your plan does not cover the medication you need, we will tell you that directly — along with what your options are.
